Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

dual tasking

- PMLiVE

Sandoz expands into Japan with €400m Aspen deal

Will gain presence in third largest generics market in the world

Roche Basel Switzerland

Roche’s Spinraza, Zolgensma rival risdiplam hits the mark in SMA

Will file for approval in US and other world markets before end of the year

- PMLiVE

Precision medicine at Blue Latitude Health

At Blue Latitude Health we have identified 90+ insights about commercialising precision medicines. Check out our video to get a run down on three core components of the commercialisation and...

Blue Latitude Health

- PMLiVE

NICE backs first cannabis-based drugs, both from GW Pharma

Approved to treat patients with epilepsy and multiple sclerosis

Novartis day

Novartis makes case for NASH candidate tropifexor

Race to market intensifies as rivals strive to win first-in-class

- PMLiVE

We’ll need more than a spoonful of sugar to counter vaccine hesitancy

By Satinder Phull

- PMLiVE

The first of many celebrations for Lucid Group at Middlesex House

Lucid Group celebrated the opening of its new offices in Fitzrovia, London on Thursday evening. The workspace in Middlesex House is incredible, allowing employees to take advantage of well-designed creative,...

Lucid Group Communications Limited

- PMLiVE

Lucid Group welcomes three new graduates ahead of the 2020 Futures Academy

Three new graduates have joined the Lucid Group family ahead of the launch of the 2020 Futures Academy in January.Having completed a Natural Sciences degree from Lancaster University, Tom Harrison...

Lucid Group Communications Limited

- PMLiVE

Boris Johnson pledges fast-track visas for key NHS workers

New system will accelerate cut-price visas for doctors and nurses

- PMLiVE

Personalised medicine can improve treatment, but access still an issue

Barriers to access could harm uptake of potentially transformative therapies

- PMLiVE

Teva names new CFO and bulks up its opioid liability fund

Opioid liability issue overshadowed the company's Q3 results

Understanding the evolving CAR-T market

In 2017 the approval of the first CAR-T treatment took the world by storm, transforming the way cancer is treated, but two years later more than 500 CAR-Ts are in...

Blue Latitude Health

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links